March 4, 2015 — The U.S. Food and Drug Administration (FDA) has approved the Xarelto Starter Pack for deep vein thrombosis (DVT) and/or pulmonary embolism (PE) treatment. The starter pack was designed to help simplify the dosing for the initial 30-day treatment period when patients are at greatest risk of having another DVT or PE.
Xarelto (rivaroxaban) was a factor Xa inhibitor approved for DVT/PE treatment and reducing the risk of their recurrence in November 2012.
The Xarelto Starter Pack will help guide physicians and patients through the initial treatment process for DVT/PE.
Most patients diagnosed with DVT/PE receive their initial treatment in the hospital and are referred to outside healthcare providers for follow-up and ongoing treatment. The Xarelto Starter Pack helps reduce challenges faced by patients and providers by providing sufficient drug supply to be administered during the all-important 30-day period when patients are most vulnerable to another event. Also, it gives the patient time to follow up with their primary care physician after leaving the hospital for further evaluation and ongoing care.
For more information: www.janssenpharmaceuticalsinc.com